CONMED (NYSE:CNMD) vs. Stereotaxis (NYSE:STXS) Critical Contrast

CONMED (NYSE:CNMD) and Stereotaxis (OTCMKTS:STXS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Volatility & Risk

CONMED has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Profitability

This table compares CONMED and Stereotaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CONMED 0.05% 8.31% 3.31%
Stereotaxis -14.80% -1,456.01% -20.71%

Valuation & Earnings

This table compares CONMED and Stereotaxis’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CONMED $955.10 million 2.47 $28.62 million $2.64 31.26
Stereotaxis $29.35 million 8.96 $120,000.00 N/A N/A

CONMED has higher revenue and earnings than Stereotaxis.

Analyst Recommendations

This is a breakdown of current recommendations for CONMED and Stereotaxis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED 0 0 0 0 N/A
Stereotaxis 0 0 3 0 3.00

Stereotaxis has a consensus price target of $8.17, suggesting a potential upside of 127.48%. Given Stereotaxis’ higher probable upside, analysts clearly believe Stereotaxis is more favorable than CONMED.

Institutional and Insider Ownership

20.8% of Stereotaxis shares are held by institutional investors. 5.4% of CONMED shares are held by company insiders. Comparatively, 34.9% of Stereotaxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Stereotaxis beats CONMED on 6 of the 11 factors compared between the two stocks.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; and endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

About Stereotaxis

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.